The aim of our group is to identify PKC (protein kinase C) in vivo function by analysing individual PKC knockouts we have generated over the past few years. The general approach we are using to identify target tissues and/or defined cell populations within the mouse for further investigation is a detailed expression analysis of individual PKC isoforms. For these purposes, we have established several specific tools in the past that allow us to follow up isoform-specific PKC expression on a very precise level. Doing so, we have started to investigate PKC expression profiles under various tumour conditions in mice. As predicted, we were able to identify various PKC isoforms to be either up-or down-regulated during the development and progression of certain tumours, implying that these isoforms are substantially linked to the biology of these tumours. In order to prove this hypothesis, we then crossed relevant PKC knockout lines on the appropriate tumour background and analysed tumour growth and progression under PKC-deficient conditions. Exemplary of this approach, recent data generated with PKCα-deficient APC Min (adenomatous polyposis coli) mice identify PKCα in this system acting as a tumour suppressor instead of being a promoter as suggested from PMA data.
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Abstract
The aim of our group is to identify PKC (protein kinase C) in vivo function by analysing individual PKC knockouts we have generated over the past few years. The general approach we are using to identify target tissues and/or defined cell populations within the mouse for further investigation is a detailed expression analysis of individual PKC isoforms. For these purposes, we have established several specific tools in the past that allow us to follow up isoform-specific PKC expression on a very precise level. Doing so, we have started to investigate PKC expression profiles under various tumour conditions in mice. As predicted, we were able to identify various PKC isoforms to be either up-or down-regulated during the development and progression of certain tumours, implying that these isoforms are substantially linked to the biology of these tumours. In order to prove this hypothesis, we then crossed relevant PKC knockout lines on the appropriate tumour background and analysed tumour growth and progression under PKC-deficient conditions. Exemplary of this approach, recent data generated with PKCα-deficient APC Min (adenomatous polyposis coli) mice identify PKCα in this system acting as a tumour suppressor instead of being a promoter as suggested from PMA data.
PKC (protein kinase C) represents a gene family of nine independent gene loci in mammals distributed over the whole genome. Due to biochemical properties and sequence homologies, PKCs are divided into three subfamilies: cPKCs (conventional PKCs, also called classical PKCs; PKCα, PKCβ and PKCγ ), nPKCs (novel PKCs; PKCδ, PKCε, PKCη and PKCθ) and aPKCs (atypical PKCs; PKCζ and PKCλ/ι). The basic activation modus operandi of cPKC and nPKC isoforms typically involves, besides other features, recruitment to membranes and interaction with and allosteric activation by DAG (diacylglycerol). In the case of aPKCs, general activation mechanisms are different; thus the classical pathways including the activation of phospholipases C and their subsequently generated second messengers InsP 3 and DAG are not necessarily required for activation. Instead, aPKC activation can be driven by interaction with the Cdc42 (cell division cycle 42)-GTP-PAR6 (partitioning defective 6) complex, which binds to the PB1 domain of aPKCs. Alternatively, the activation of the PI3K (phosphoinositide 3-kinase) pathway can also lead to the activation of aPKCs. In each case, the allosteric effects of these lipid-protein interactions on PKC isoforms lead to a loss of the inhibition exerted by an inhibitory pseudosubstrate sequence that otherwise occupies the catalytic site of the enzyme [1] . Upon activation, individual PKC isoforms have been shown to participate in signalling pathways regulating a plethora of biological functions, including cell growth, differentiation, apoptosis, transformation and tumour development [2] . Nevertheless, clear statements about PKC isoform specificity in vivo covering the above processes are rather limited. This is due to the fact that in vitro most PKCs behave very similarly and experimental approaches are limited by the fact that no real selective pharmacological inhibitors are available. This becomes even more complex since all cells and/or tissues do express more than one PKC isoform that possibly can act in a redundant manner. There is evidence that the wide spectrum of PKC-mediated signalling is organized by isotype specificity that, despite the broad overlapping substrate specificities, is defined via unique expression patterns, intracellular localization and specific binding partners [3, 4] . The initial finding in 1982 by Castagna et al. [5] that PKC was at that time the only receptor for phorbol ester in mammalian cells and becomes constitutively activated by binding brought this protein family to the attention of many researchers simply due to the fact that phorbol esters (PMA) are a widely used experimental tool. This early observation also connected PKC in vivo function to tumour development and defined PKC as a tumour promoter. But in this case too, a clear statement about the involvement of individual PKC isoforms and the underlying mechanism in these processes is not really possible. Instead, even reports on one PKC isoform may vary with different cell types or in vivo systems analysed (see e.g. [6] ).
Particularly the issue of identifying and analysing isoform-specific PKC in vivo function is the main focus of our laboratory. To do so, we have chosen the gene targeting approach in mice and knocked-out over the last couple of years eight of the nine existing PKC genes. During the course of the subsequently followed phenotypical analysis of these mutant mouse lines, it became obvious that detailed expression data of individual PKCs are mandatory for a thorough analysis. Due to the inconsistencies of published data about isoform-specific expression of PKCs, we have established and verified various tools (such as specific RNA in situ probes, isoform-specific antibodies and reporter alleles in mice using the endogenous PKC promoter) in order to analyse PKC expression pattern in depth (see e.g. [7, 8] ). By so doing, we are generating data about individual PKCs, indicating their expression during embryonic development as well as in distinct cell populations and tissues in adults. It also enables us to monitor changes in these patterns when metabolic changes occur within the organism and/or when certain diseases develop like, for example, a tumour. Since PKC's in vivo role has always been linked to processes such as proliferation, apoptosis and differentiation, and due to the fact that PKCs are PMA responders and thus supposed to be involved in tumour development, we decided to analyse the contribution of individual PKC isoforms in the development of cancer using defined cancer models in mice in combination with the individual PKC knockout lines established in the group. As proof of principle, we decided to start with the APC Min (adenomatous polyposis coli) mouse model, which represents a widely used model for studying colorectal cancer biology. Following our dogma 'from expression to function', we first analysed the PKC expression profile in polyps of APC Min mutants by RNA in situ hybridization followed by a PKC-specific quantitative PCR analysis (see Figures 1 and 2) . In both experimental set-ups, we were able to identify some PKC isoforms that were, to different extents, up-regulated, as expected for genes supposed to trigger tumour formation. To our surprise, we also identified two isoforms (PKCα and PKCζ ) to be down-regulated in 
APC
Min polyps (see Figure 1 ) which, per definition, defines them as possible tumour suppressors. In order to verify these findings in vivo, we decided to cross the corresponding PKC knockouts on to the APC Min background and evaluate the polyp-and subsequent tumour-formation in these mutants. The results of this study [9] clearly indicated that PKCα deficiency results in a more pronounced APC Min phenotype; therefore we detected more polyps at earlier time points that consequently led to earlier death of the APC Min /PKCα −/− genotype. Interestingly, the PKCα mutants on their own appeared not to be cancer-prone. In contrast, the APC Min /PKCζ −/− genotype did not show any difference compared with the APC Min mutation alone. This is most likely to be due to the attendance of the other aPKC isoform (PKCι/λ), which is highly homologous with PKCζ and is supposed to be able to compensate for PKCζ function (M. Leitges, unpublished work). Also, supporting this notion, PKCι/λ was shown to be dramatically up-regulated in polyps of APC Min animals ( Figure 2) . A final conclusion on this topic based on mouse genetic approaches is limited at this end by the observed embryonic lethality of the PKCι/λ −/− mutation. Aiming to analyse the mechanism underlying the APC Min /PKCα −/− phenotype, we first focused on the Wnt target genes but were not able to identify any additional alteration different from that caused already by the APC mutation on its own. In contrast, a transcriptional profile of wild-type versus PKCα-deficient small intestine revealed that a relatively small number of genes are deregulated. Of particular interest was the up-regulation of two well-known oncogenes, Btc and Jun, which in part are described as downstream targets of the EGFR (epidermal growth factor receptor) signalling pathway. Even more interesting, we subsequently were able to show that the expression domain of Btc has shifted in the PKCα deficiency from the Paneth cells in the wild-type to epithelial and stroma cells all over the intestine.
According to our in vivo observation, the transcriptional up-regulation of Btc and Jun gets even more pronounced in APC Min /PKCα-deficient tumour tissue. In anticipation that Btc represents a ligand for the EGFR, we speculated that an up-regulation and dislocation of its expression domain might result in a hyperactivation of this signalling pathway. As a common indicator of EGFR activity, we chose the MAPK (mitogen-activated protein kinase). In fact, as shown by the strongly increased ERK1/2 (extracellular-signal-regulated kinase 1/2) phosphorylation signal all over the place in the APC Min /PKCα −/− mutation, it became readily supported that EGFR signalling is up-regulated. Finally, we were also able to show, using a set of phosphospecific EGFR antibodies, that the EGFR activity follows the pattern of Btc expression and ERK1/2 activity. Nevertheless, how exactly PKCα modulates EGFR signalling either by reducing the threshold of the receptor or by extending its activity needs to be further analysed in the future.
In summary, our phenotypical analysis of PKCα knockouts in the context of colorectal cancer identifies a new and unexpected in vivo function of PKCα, defining this isoform unexpectedly as a tumour suppressor. This is of particular importance since so far all classical and novel PKC isoforms have been described as tumour promoters due to their PMA responsiveness. Based on this assumption, numbers of pharmacological compounds have been or are about to be developed in order to inhibit isoform-specific PKC function including intentions to use these compounds in more or less broad applications designed for human cancer therapies. Especially for PKCα, which has been widely accepted to be a target for inhibition in cancer therapies, we now have shown that at least in certain colorectal cancers it might be counterproductive to block PKCα in vivo function. These studies now need to be extended to alternative colon cancer models in order to generalize these findings. It is interesting to mention at this point that the remaining classical PKCβ isoform in the intestine shows exactly the opposite behaviour using mouse genetic approaches. Either in a transgenic overexpression system [10] or using the knockout [11] , PKCβ was identified as a tumour promoter thus representing a good drug target for inhibition under these circumstances. Taking into account that most pharmacological PKC inhibitors do show at least some cross-reactivity to other PKC isoforms, it would be interesting to see in the future using for example the PKCα/β double knockout as a tool whether PKCα in vivo function dominates PKCα or vice versa. Thus one future aim of our group will be the further identification and analysis of molecular mechanisms of PKC in vivo functions in various cancer models in mice and thereby pin down PKC isoforms that might be good and more precise targets for drug development in cancer therapies.
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